Digestive Disease Week

Digestive Disease Week

Source:

Sands B, et al. Abstract 775d. Presented at: Digestive Disease Week; May 21-23, 2021 (virtual meeting).

Disclosures: Sands reports consulting for AbbVie, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Inotrem, Janssen, Johnson & Johnson, Kallyope, Pfizer, Protagonist Therapeutics, Surrozen and Takeda Pharmaceuticals; serving on an advisory committee or review panel for Abivax, Arena Pharmaceuticals, Immunic, Ironwood Pharmaceuticals, Lilly, Prometheus Biosciences IBD and Target RWE. Please see the study for all other authors’ relevant financial disclosures.
June 09, 2021
1 min watch
Save

VIDEO: Stelara, Humira safely, effectively treat CD

Source:

Sands B, et al. Abstract 775d. Presented at: Digestive Disease Week; May 21-23, 2021 (virtual meeting).

Disclosures: Sands reports consulting for AbbVie, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Inotrem, Janssen, Johnson & Johnson, Kallyope, Pfizer, Protagonist Therapeutics, Surrozen and Takeda Pharmaceuticals; serving on an advisory committee or review panel for Abivax, Arena Pharmaceuticals, Immunic, Ironwood Pharmaceuticals, Lilly, Prometheus Biosciences IBD and Target RWE. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Stelara and Humira demonstrated rapid onset of action and effectiveness in the treatment of patients with moderate to severe Crohn’s disease, Bruce Sands, MD, Icahn School of Medicine, told Healio Gastroenterology.

In a multicenter, blinded, active-controlled study, researchers randomly assigned 386 biologic-naive patients 1:1 to receive either Stelara (ustekinumab, Janssen) or Humira (adalimumab, AbbVie) for the treatment of their moderate to severe CD. The primary endpoint was clinical remission at 52 weeks, which 65% of patients treated with ustekinumab and 61% of patients treated with adalimumab achieved.

“This study was the first head-to-head study of biologics in patients with CD and both ustekinumab and adalimumab were highly effective in this treat-through study design for biologic-naive patients,” Sands concluded. “[T]his may inform our use of these biologic agents in first-line therapy for patients with CD and hopefully will contribute greatly to the field.”